Navigation Links
Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
Date:3/15/2011

SEATTLE, March 15, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2010.

Financial ResultsTotal operating expenses for the three months ended December 31, 2010 were $9.5 million, compared to $5.7 million for the same period in 2009. Total operating expenses for the year ended December 31, 2010 were $32.2 million, compared to $22.2 million in 2009. The increase in operating expenses for the fourth quarter and year ended December 31, 2010 was primarily due to increased research and development expense related to the Company's Phase 3 clinical program evaluating OMS103HP in arthroscopic ACL reconstruction as well as its Phase 2b clinical trial evaluating OMS302 in patients undergoing cataract surgery. The increase was also due to expenses related to the advancement of Omeros' preclinical-stage pipeline and increased costs associated with being a public company.

For the fourth quarter ended December 31, 2010, Omeros reported a net loss of $7.2 million, or $0.34 per share, compared to a net loss of $5.6 million, or $0.28 per share, for the same period in 2009. For the year ended December 31, 2010, the Company reported a net loss of $29.3 million, or $1.37 per share, compared to a net loss of $21.1 million, or $2.92 per share, in 2009.

At December 31, 2010, Omeros had cash and cash equivalents and short-term investments of $42.0 million, compared with $60.3 million as of December 31, 2009.

"We have reported significant progress across our development programs in recent months, including obtaining substantial funding for our GPCR program, successfully completing a Phase 1/2 program evaluating our
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced that the Company will release results ... 7, 2014 before the opening of the U.S. financial ... that day at 8:30 a.m. ET to discuss results ... presentation slides to be used during the call will ...
(Date:7/31/2014)... , July 31, 2014  Decision ... changes brought about by the Affordable Care ... and prescribing of pharmaceutical therapies. The ACA ... beneficiaries through new regulations and expanded access ... in the health exchanges—state-based marketplaces set up ...
(Date:7/31/2014)... 2014 Touro University California,s College of Pharmacy ... the recipient of a $150,000 grant by the Joseph ... to increase research and classroom space on its campus. ... the study of health sciences, and will help us ... interests of our students," said Shelley Berkley , ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Touro University California Garners Grant From Long Foundation 2
... -- Global Information, Inc. (GII) presents " Computed Tomography ... Market Forecasts to 2017 " by GlobalData.  ... global Computed Tomography (CT) systems market to be worth ... systems and low-dose CT systems, the market is forecast ...
... -- Physicians, Capital Investments, LLC (PCI/the Company) a leader ... is pleased to announce that Becker,s ASC Review has ... in the ASC Industry to Know." This publication recognizes ... through their work with ASC-related companies, surgery centers and ...
Cached Medicine Technology:GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market 2GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market 3GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market 4Physicians' Capital Investments Announces Pedro Vergne-Marini, MD Named to Becker's ASC Review "350 People in the ASC Industry to Know" 2Physicians' Capital Investments Announces Pedro Vergne-Marini, MD Named to Becker's ASC Review "350 People in the ASC Industry to Know" 3Physicians' Capital Investments Announces Pedro Vergne-Marini, MD Named to Becker's ASC Review "350 People in the ASC Industry to Know" 4
(Date:8/1/2014)... at the Institute of Bioengineering and Nanotechnology (IBN), ... Singapore (NCCS) have co-developed the first molecular test ... in kidney cancer patients. This breakthrough was recently ... top urology journal. , According to IBN ... our expertise in molecular diagnostics and cancer research, ...
(Date:8/1/2014)... St. Christopher's Hospital for Children announced that they ... with Ed Begley Jr, airing later this year 2014, ... St. Christopher's Hospital for Children offers a wide range ... 21 years of age. With over 220 pediatric specialists, ... autism and childhood obesity. , “St. Christopher’s is ...
(Date:8/1/2014)... Jordan, Utah (PRWEB) August 01, 2014 ... company MonaVie, who completes its 500th week of paying ... since the company was founded in January 2005 total ... countries throughout the world. The company pays commissions in ... HUF, ILS, JPY, MYR, MXN, NZD, PLN, USD, SGD, ...
(Date:8/1/2014)... BellasDress has recently showcased its beautifully ... season’s gorgeous styles. The company’s lot of hot styles, ... outfits, one shoulder chiffon outfits and high low outfits. ... elegant purple prom dresses. As one of the most ... product quality. Thus, all its items are of superb ...
(Date:8/1/2014)... CentraComm, a leading managed IT security ... the Pure Storage® Authorized Reseller program. , ... experience designed to meet the rigorous resiliency, scalability, ... diverse markets, and for a variety of high ... years. , The Pure Storage FlashArray was ...
Breaking Medicine News(10 mins):Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2Health News:BellasDress Creates Must-have Purple Prom Dresses for Prom Attendees 2Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 2Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 3
... , ... Products at E3 Expo To Show Off Consumer Market Appeal and Wellness Benefits for Gamers ... Los Angeles, CA (Vocus) ... innovative musical instruments and music software to enable people of all ages and skill levels ...
... ... of your control environment, SAS 70 reports have become a credible marketing tool to ... ... is a leading provider that specializes solely in SAS 70 readiness reviews, SAS 70 Type ...
... promising. Sorafenib is used for advanced liver and kidney ... stem cells in pancreatic cancer. The team led by ... Molecular Oncosurgery, a group of the Department of Surgery ... W. Bchler) in cooperation with the German Cancer Research ...
... with the right information, physicians can play a stronger ... drugs proven to prevent asthma attacks, according to researchers ... finds patients are more likely to routinely take inhaled ... watch over their medication use and reviewed detailed electronic ...
... ... same-day healthcare appointments online. , ... Chicago, IL (PRWEB) June 15, 2010 -- ZocDoc, the website to ... metropolitan area. The company’s move was chosen by thousands of users, who were asked ...
... ... process should not be undertaken without legal representation, urges American Residential Law Group. ... Fort Lauderdale, FL ... foreclosure not to go through the mortgage modification process without viable legal help on ...
Cached Medicine News:Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 2Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 3Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 4Health News:Can a SAS 70 Audit Create a Competitive Advantage for Your Business? 2Health News:Can a SAS 70 Audit Create a Competitive Advantage for Your Business? 3Health News:Can a SAS 70 Audit Create a Competitive Advantage for Your Business? 4Health News:New combination effective against pancreatic cancer 2Health News:Study: Getting patients to take their asthma meds 2Health News:Chicago Votes for Improved Healthcare with ZocDoc 2Health News:American Residential Law Group Urges Homeowners Not to “Go It Alone” During Mortgage Modification 2
Galaxy Single Piece PMMA Lens with UV Absorber....
Liberty Single Piece PMMA Lens with UV Absorber....
Optical implants for the replacement of the human crystalline lens in the visual correction of aphakia....
... II is a sterile nonpyrogenic, transparent viscoelastic ... II contains 12 mg/ml of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: